scholarly journals CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

Blood ◽  
2015 ◽  
Vol 125 (1) ◽  
pp. 90-101 ◽  
Author(s):  
Ruth Scheicher ◽  
Andrea Hoelbl-Kovacic ◽  
Florian Bellutti ◽  
Anca-Sarmiza Tigan ◽  
Michaela Prchal-Murphy ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Activation ◽  
Transcriptional Regulator ◽  
Leukemic Stem Cell ◽  
Key Points

Key Points CDK6 acts as a transcriptional regulator to suppress Egr1 in HSCs and LSCs, allowing their activation. Cdk6 −/− HSCs fail to contribute to repopulation in competitive transplants, and BCR-ABLp210+Cdk6−/− LSCs fail to inflict disease.

scholarly journals CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

2018 ◽  
Vol 2 (14) ◽  
pp. 1738-1749 ◽  
Author(s):  
Ying-Ping Jiang ◽  
Bob Y. Liu ◽  
Quan Zheng ◽  
Swapna Panuganti ◽  
Ruoying Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Leukemic Stem Cell ◽  
Cell Targeting ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Key Points ◽  
Acute Myeloid ◽  
Antibody Drug

Key Points CLL1-ADC targets both AML blasts and LSCs. Unlike CD33-ADC, CLL1-ADC does not affect normal HSCs.

scholarly journals Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia

2018 ◽  
Vol 2 (13) ◽  
pp. 1572-1579 ◽  
Author(s):  
Anne-Sophie Bouillon ◽  
Monica S. Ventura Ferreira ◽  
Shady Adnan Awad ◽  
Johan Richter ◽  
Andreas Hochhaus ◽  
...  
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Myeloid Cells ◽  
Leukemic Stem Cell ◽  
Molecular Remission ◽  
Telomere Shortening ◽  
Key Points ◽  
Tki Treatment

Key Points TL in LSCs is significantly shortened at diagnosis of CML and correlates with LSC burden. TL in nonleukemic myeloid cells in deep molecular remission is unaffected by long-term TKI treatment.

Sign in / Sign up

Export Citation Format

Share Document